[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Institute of Neurological Disorders and Stroke (NINDS)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":555},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,53,0,25,[9,49,72,100,125,165,178,188,197,206,215,238,264,287,312,333,359,383,407,427,447,472,492,515,532],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053705","screening-for-social-determinants-of-health-sdoh-and-cognitive-function-in-individuals-with-history-of-stroke-100053705",false,"NCT06615973","Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke","Understanding Stroke Outcomes: Stroke Resilience, Infarct Burden, and Long-Term Cognition","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Adults aged 18 or older.\n* Previous participant in the Natural History of Stroke with an interpretable baseline MRI scan, NIHSS measured at baseline or discharge, and admission diagnosis of ischemic stroke.\n* Fluent in English or Spanish\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this\n\nstudy:\n\n-Modified Rankin Scale (mRS) = 6 at any follow-up (usually up to 90 days) in the Natural History of Stroke study (mRS = 6 indicates the participant is dead).","ALL","18 Years","99 Years",{"count":21,"type":22},450,"ESTIMATED","OBSERVATIONAL","Background:\n\nStroke is the fifth leading cause of death in the United States. It is also a leading cause of disability. More than 70% of people who survive strokes have mental impairment or dementia. Medical factors, such as the severity of the stroke, affect whether a person will have mental impairment afterward. But social factors, such as education and ethnicity, seem to play a role as well. Researchers want to learn more about how social and lifestyle factors affect a person s chances of maintaining mental functions after a stroke.\n\nObjective:\n\nTo better understand how social and lifestyle factors affect the risk of mental impairment after a stroke.\n\nEligibility:\n\nPeople aged 18 years and older who had a stroke and a brain scan while they were enrolled in NIH Study 01N0007 (Natural History of Stroke Study).\n\nDesign:\n\nParticipants will have 1 study visit, by telephone. The call will last about 45 minutes. Participants will talk about their health since their stroke. They will answer questions about themselves. Topics will include:\n\n* Their race\n* Education\n* Ethnicity\n* Employment\n* Marital status\n* Residence address\n* Recent health history\n* Medical insurance\n\nThey will have tests of their memory, attention, and language skills. They will repeat numbers and words forward and backward.\n\nResearchers will look at the data and imaging scans collected during participant s enrollment in NIH Study 01N0007. This data will include:\n\n* The hospital that first saw the participant at the time of their stroke.\n* The type of imaging that was first used then.\n* The primary diagnosis at admission.\n* Other medical details.",[26,27,28,29],"Stroke","Brain Disease","Vascular Diseases","Cerebrovascular Disorder",[26,31,32,33,34,35],"Social Determinants of Health","Cognition","cerebrovascular health","Magnetic Resonance Imaging (MRI)","vascular health","RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":22},"2026-07-16",{"date":44,"type":22},"2027-02-01",{"name":46,"class":47},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":48},"100053967","distinguishing-tics-and-functional-tics-using-clinical-neurophysiological-techniques-100053967","NCT07137442","Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniques","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Capacity to provide informed consent (self-consent)\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 18-80\n* Agreement to adhere to Lifestyle Considerations prior to and during the physiological testing visit.\n\nInclusion criteria for patients with functional tics or tics\n\n\\- Diagnosed with functional motor tics or motor tics\n\nInclusion criteria for healthy controls\n\n\\- Have no neurological or psychiatric disorders established by history and physical\u002Fneurological examination\n\nEXCLUSION CRITERIA:\n\n* Self-reported consumption of \\>14 alcoholic drinks\u002Fweek\\* for a man and \\>7 alcoholic drinks\u002Fweek for a woman\n* Use of prescription drugs and other illicit drugs that may suppress tics such as dopamine blocking agents and antipsychotics during a certain time period prior to the\n\nneurophysiological testing session.\\*\\*\n\n* Clinically significant abnormal movements on neurological examination except for tics.\n* Contraindications to EEG or EMG procedures, including skin lesions at electrode sites or hypersensitivity to electrode materials.\n* History of or current brain tumor, stroke, head trauma with loss of consciousness.\n* Epilepsy or seizures in the past 12 months.\n* Have a Baclofen pump, or have neurostimulators for pain.\n* Pregnant women\n* Self-reported current major depression or Beck Depression Inventory II (BDI-II) score \\>19, Generalized Anxiety Disorder 7-item scale (GAD-7) score \\> 9, or any major current psychiatric illness.\n* Presence of any metal in the eye or skull area such as a brain stimulator, shrapnel, surgical metal, clips in the brain, cochlear implants, metal fragments in the eye.\n* Presence of pacemaker, intracardiac lines, implanted pumps or stimulators.\n* Unable to comply with the requirements of the study procedures.\n* Vocal tics only tested with Modified Rush Video-Based Tic Rating Scale.\n* Low Premonitory Urge for Tics Scale (PUTS) score \\\u003C 9 (maximum 36) with low willingness for tics (patient groups only, not applicable in healthy volunteers).\n\n  * Note: 1 standard alcoholic drink is 0.6 ounce (14 grams) of pure alcohol.\n\n    * Note: The certain time period depends on different drugs used. Five half-lives will be selected. The drug is considered effectively eliminated from the body after this time period because the concentration of the drug reaches around 3% of the orininal concentration.","80 Years",{"count":57,"type":22},75,"Background:\n\nTics are involuntary movements and vocalizations. Some tics are organic: They are related to diagnosed disorders. Sometimes tics have other causes, such as problems with how the brain and body send and receive messages. These are called functional tics. It can be difficult to tell the difference between these 2 types of tics. Doctors need to know more so they can make more accurate diagnoses.\n\nObjective:\n\nTo learn more about the difference between functional and organic tics.\n\nEligibility:\n\nAdults aged 18 to 80 years who have a tic that causes involuntary movements. Healthy volunteers with no tics are also needed.\n\nDesign:\n\nParticipants will have one 4-hour clinic visit. The visit may be done in 1 or 2 days. Participants will refrain from consuming alcohol or caffeine before the visit. They may have a physical exam.\n\nParticipants will wear two types of sensors:\n\nElectromyography (EMG): Adhesive disks with sensors will be attached to the skin above some muscles. These disks will record electricity in the muscles as the participant moves.\n\nElectroencephalography (EEG): Sensors will be placed on the participant s scalp. The sensors may be adhered directly, or the participant may wear an electrode cap. The sensors will detect brain waves.\n\nParticipants will rest while seated in a chair. Their involuntary tics will be monitored with the EMG and EEG. Then they will be asked to make movements to mimic their tics. Healthy volunteers will also rest; then they will be asked to perform movements that mimic tics.\n\nParticipants will have their blink reflex tested. EMG sensors will be placed on the muscles near the eyes. Electrical pulses will be used to stimulate blinking.\n\nParticipants will answer questionnaires about their tics and their health....",[60,61],"Tics","Functional Tics",[60,63,64,65,66],"Functional tics","EEG","Blink Reflex","Pre-pulse inhibition",{"date":39,"type":40},{"date":42,"type":22},{"date":70,"type":22},"2034-08-01",{"name":46,"class":47},{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":48},"100053555","phase-1-phase-i-open-label-safety-trial-of-pembrolizumab-for-neurological-post--acute-sequelae-of-sars-cov-2-pd1-pasc-i-100053555","NCT07388550","Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)","Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post-Acute Sequelae of SARS-CoV-2 (PD1-PASC I)","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Male or female, aged at least 18 or older.\n\n  --Documentation of the SARS-CoV-2 infection that led to development of PASC confirmed either by a positive testing by a commercial laboratory or a positive home test followed by confirmatory nucleocapsid antibody testing.\n* Previously diagnosed with mild-moderate COVID-19 (WHO Clinical Progression Scale between 2-5. Participants who had severe acute COVID-19 requiring hospitalization or ICU care are excluded.\n* If participants had multiple SARS-CoV-2 infections, they would need to be at least 6 months after the last infection.\n* All participants would need to have a negative SARS-CoV-2 nasal swab at the time of enrollment.\n* Exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent PASC symptoms after recovering from a SARS-CoV-2 infection. These include symptoms such as fatigue, cognitive difficulties, sleep disturbances, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation, or strength. Symptoms must persist for at least 6 months after the diagnosis of acute COVID-19.\n* All participants will have PD-1 expression on CD8 T cells that is one SD above the mean value of normal controls as established in the SINS Lab and published previously.\n* Moderate to severe PASC symptom severity, as determined using PCFS (minimal score of 3).\n* Ability of participant to understand and sign a written informed consent document.\n* Prior completion of a clinical brain MRI after the diagnosis of COVID-19, or willingness to complete a brain MRI.\n* Agrees not to have vaccinations over the course of the study.\n* Participants of childbearing potential must agree to use a combination of contraception (defined as two forms of effective birth control) or have had surgical sterilization, from the time of enrollment until 4 months after the dose of study drug.\n* Participants capable of sperm donation must agree to not donate sperm from the time of enrollment until 4 months after the dose of study drug.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* For participants who have not completed a brain MRI since onset of symptoms: inability to complete brain MRI with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, eGFR \\\u003C45 mmol\u002FL, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine.\n* Contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets \\\u003C 50,000\u002FuL, PT or PTT \\>1.5 x ULN for the NIH Clinical Center, if risk of lumbar puncture is increased for other reasons such as space occupying lesion, skin infection at site of the puncture or otherwise inability to complete the procedure.\n* A condition that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. This could include traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy.\n* Any premorbid medical condition that would potentially cause fatigue and exercise intolerance. This includes many chronic medical diseases, such as congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease, severe arthritis, uncontrolled asthma, renal failure, fibromyalgia, and ME\u002FCFS.\n* Symptom severity that makes it impossible for the participant to travel to NIH.\n* Received a SARS-CoV-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the study.\n* Prior treatment for PASC with immunomodulatory therapies such as check point inhibitors which in the opinion of the investigators could impact the outcome of this study.\n* Current medications include oral steroids or other immunosuppressive medications which in the opinion of the investigators could impact the outcome of this study.\n* Active participation in a clinical protocol which includes any intervention that may affect the results of the current study.\n* Abnormal anti-thyroid panel (anti-TPO and anti-TG) test at screening visit.\n* ANA titer of 1:80 or greater, positive anti-CCP.\n* Abnormal screening blood tests exceeding any of the limits defined below or as deemed exclusionary by the investigators on review at baseline:\n\n  * Aspartate aminotransferase and alanine aminotransferase values \\>2x upper limit of normal precluding the use of acetaminophen\n  * Fasting triglyceride \\> 300 mg\u002FdL.\n  * Total bilirubin \\>2x upper limit of normal (unless participant has Gilbert syndrome)\n  * Creatinine Clearance or eGFR \\\u003C60 ml\u002Fminute (adjusted for race)\n  * Hemoglobin \\\u003C 10 g\u002FdL\n  * Absolute neutrophil count \\\u003C 1000\u002Fmicroliter\n  * Platelet count \\\u003C130,000\u002Fmm3 (if platelet clumping is present on hematology slide review, platelet count \\\u003C100,000\u002Fmm3 is considered exclusionary to study)\n  * Hemoglobin A1c \\>= 6%\n  * Thyroid-stimulating hormone (TSH) and adrenocorticotropic hormone (ACTH) within normal limits. If TSH is not within normal limits then the participant may be eligible if thyroxine (T4) is within normal limits. Participants are not excluded if they are on a stable dose of replacement thyroid medication; dose may be adjusted as needed.\n* Previously documented anaphylaxis or severe systemic reaction to check point inhibitors, acetaminophen, or diphenhydramine.\n* A severe psychiatric condition, which based on the assessment of the study investigators, will impact the ability to complete the study.\n* Pregnancy or planning to get pregnant.\n* Currently lactating\u002Fbreastfeeding.\n* Current or previous malignancy. A history of malignancy that has fully resolved with surgical resection only (e.g. no chemotherapy, radiation therapy, or immunotherapy) will be allowed.\n* Current or past substance use disorder within last five years. Marijuana use within the past five years will not be an exclusion.\n* Infection with HIV, tuberculosis, hepatitis B or C.","110 Years",{"count":81,"type":22},15,"INTERVENTIONAL",[84],"PHASE1","Background:\n\nSARS-CoV-2 is the virus that causes COVID-19. Some people who recover from an acute COVID-19 infection may continue to have symptoms that persist for months or years. These can include neurological symptoms, such as headaches, loss of taste or smell, dizziness, or trouble walking. Pembrolizumab is a drug approved to treat certain cancers. Researchers think this drug might reduce long-term neurologic symptoms after a COVID-19 infection.\n\nObjective:\n\nTo test pembrolizumab in people with ongoing neurologic symptoms of COVID-19.\n\nEligibility:\n\nPeople aged 18 years or older who had COVID-19 at least 6 months ago and have ongoing neurologic symptoms.\n\nDesign:\n\nParticipants will have 7 clinic visits in 7 months.\n\nParticipants will be screened. They will have a physical exam with blood tests. Swabs will be used to collect cells from inside the mouth and nose. They may opt to have an imaging scan.\n\nParticipants will also have other tests before they are given the study drug. These include eye and skin exams; tests of their memory and thinking; and tests of involuntary body functions, such as heart rate, blood pressure, sweating, and digestion. Their grip strength and walking pace will be measured. They will wear a heart rate monitor for 24 hours. They will wear devices on a wrist and thigh to measure activity for 10 days.\n\nParticipants will have a lumbar puncture (spinal tap): A thin needle will be inserted into their lower back to draw out a sample of the fluid around their spinal cord.\n\nPembrolizumab is given through a needle inserted into a vein. Participants will receive 1 dose of the drug.\n\nParticipants will have 4 follow-up visits over 6 months. Tests may be repeated during these visits.",[87],"Post-Acute COVID-19 Syndrome",[89,90,91,92,93],"PASC","Long Covid","COVID","COVID-19","Postacute Sequelae of COVID","NOT_YET_RECRUITING",{"date":39,"type":40},{"date":42,"type":22},{"date":98,"type":22},"2028-01-01",{"name":46,"class":47},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":107,"maxAge":19,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":48},"100053891","ultra-low-field-ulf-point-of-care-poc-mri-system-for-brain-morphology-and-pathology-100053891","NCT06203626","Ultra-Low Field (ULF) Point-of-Care (POC) MRI System for Brain Morphology and Pathology","Ultra-Low Field (ULF) Point Of Care (POC) MRI System for Study Brain Morphology and Pathology","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Volunteer of any gender, 3 years of age and older.\n* Adult participant: must be capable of understanding the procedures and requirements of this study and be able and willing to sign an informed consent document.\n* Minor participant: Must have a parent or guardian capable of understanding the procedures and requirements of this study who are willing to sign an informed parental consent document, and where feasible, the minor age 7 and older provides assent.\n* Either:\n\n  * Adult in good general health as evidenced by medical history or\n  * Diagnosed with a stroke, a neurological or neuro-oncological disease, or\n  * Exhibiting symptoms suggestive of neurological or neuro-oncological disease.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Unable to undergo MRI study based on screening (e.g., presence of non-MRI compatible objects).\n* Pregnancy or lactation, if contrast agent is required.","3 Years",{"count":109,"type":22},200,"Background:\n\nMagnetic resonance imaging (MRI) is a tool for getting pictures of the tissues and organs inside the body. MRI can help diagnose many injuries and diseases. But not all patients are equally likely to receive MRIs. Factors such as race or ethnicity, distance to imaging centers, mobility, and a lower income can limit some people s access to MRIs. A new ultra-low field (ULF) type of MRI, which can be used on a vehicle, may help take imaging scans to more people. But researchers need to know that UFL-MRI works just as well as standard MRIs.\n\nObjective:\n\nTo learn whether UFL-MRI is as good as standard MRI at detecting neurological disorders.\n\nEligibility:\n\nPeople aged 3 years or older who have or show symptoms of neurological disease (such as stroke, cancer, or epilepsy). Healthy adults are also needed.\n\nDesign:\n\nParticipants will have 1 or 2 study visits.\n\nAdult participants will have a physical exam. They will receive two MRI exams:\n\n* Standard MRI. They will lie still on a narrow bed that will move into a large tube. They will wear earplugs to muffle the sounds.\n* ULF-MRI. They will lie on a stretcher, and only their head will be inside a smaller tube. The noises will be quieter. They will wear earplugs to muffle the sounds.\n\nSome adults may receive a contrast agent given through a small tube attached to a needle in the arm. The contrast agent helps the researchers see differences in the body more clearly. This may be done during 1 or both MRIs.\n\nChildren will have only 1 ULF-MRI.\n\nSome participants may be invited to have additional visits for up to 6 months.",[112],"Nervous System Diseases (C10 Unique ID D009422)",[114,115,116,117,118],"MRI","Brain","Morphometry","ultra-low field MRI","Lesion",{"date":39,"type":40},{"date":121,"type":40},"2024-03-26",{"date":123,"type":22},"2027-12-31",{"name":46,"class":47},{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":132,"targetDuration":4,"studyType":82,"phases":134,"briefSummary":136,"conditions":137,"keywords":153,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":162,"leadSponsor":164,"locationsCount":48},"100053479","phase-1-novel-indenoisoquinolone-cmyctopoisomerase-1-inhibitor-lmp744-in-recurrent-glioblastoma-100053479","NCT07416188","Novel Indenoisoquinolone CMYC\u002FTOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma","Phase 1\u002FPhase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC\u002FTOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma","* INCLUSION CRITERIA:\n\nParticipant must meet all the following inclusion criteria to be deemed eligible for this study:\n\n* Participants \\>= 18 years of age\n* Tissue-based diagnosis of recurrent glioblastoma, IDH-wildtype by a neuropathologist\n* Karnofsky Performance Status (KPS) \\>60\n* Willing to use effective birth control method\n\n  --The effects of LMP744 on developing human fetuses are unknown. Therefore, females of childbearing potential and their male partners must be willing to use an effective method of contraception during the clinical study (hormonal, barrier, surgical, or abstinence) before study enrollment and for 6 months after the last dose of the study drug. If the female becomes pregnant or suspects she is pregnant while participating in this study, she must inform her treating physician immediately.\n* Agreeable to undergo craniotomy for brain biopsy and\u002For resection\n\n  --Initial diagnostic biopsy under 03-N-0164 to confirm recurrent disease and obtain pre-treatment tissue. Only participants who were not expected to able to achieve a gross total resection of tumor will be included in the study.\n* Willing and able to appoint a durable power of attorney\n* Able to provide informed consent or have a legally authorized representative (LAR) to provide consent, if incapacitated.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Pregnant and\u002For nursing females\n\n  --As LMP744 is a novel agent with the potential for teratogenic or abortifacient effects, pregnant and\u002For nursing females will be excluded from receiving drug\n* Significant medical co-morbidities that would compromise the participant s ability to tolerate LMP744 and which cannot reasonably be controlled (per the investigator s judgment, such as poorly controlled chronic kidney disease and\u002For poorly controlled congestive heart failure)\n* Social situations that would limit compliance with study requirements, such as chronic homelessness\n* Prior chemotherapy or biologic therapy completed within 4 weeks (6 weeks for nitrosoureas and mitomycin C) or a duration of 5 half-lives (whichever is shorter)\n* Additional malignancy diagnosed or requiring active treatment within 1 year of screening\n* Unable to undergo an MRI scan of the brain\n* Active autoimmune disease that requires systemic treatment within 2 years of screening\n* Cardiac disease\n\n  * \\>=2 MIs\n  * \\>=2 coronary revascularization procedures\n  * Cardiac Troponin T or I \\>= 2x the institutional upper limit of normal at screening\n  * Ejection fraction \\\u003C45% on screening echocardiogram\n* Chronic hypokalemia (K\\\u003C2.5 mmol\u002FL)\n* Human Immunodeficiency Virus (HIV)\n\n  * Known history of HIV\n  * Positive HIV 1\u002F2 at screening.\n* Active Hepatitis B or Hepatitis C infection at screening\n* Active infection requiring systemic antibacterial, antiviral or antifungal therapy \\\u003C7 days prior to initiation of study drug\n* Recipient of autologous or allogeneic T cells\n* Solid organ or tissue transplant recipients",{"count":133,"type":22},40,[84,135],"PHASE2","Background:\n\nGlioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells.\n\nObjective:\n\nTo test LMP744 in people with glioblastoma.\n\nEligibility:\n\nPeople aged 18 years or older with glioblastoma that returned after treatment.\n\nDesign:\n\nParticipants will be screened. They will have a surgery to remove a small sample of tumor tissue (biopsy) from the brain. This will be done under protocol 03-N-0164. They will stay in the clinic for 1 night. They will also have imaging scans and tests of their heart function.\n\nParticipants will have a central line installed: A flexible tube will be inserted into a vein in the chest. It will be attached to a port under the skin. This port will be used to draw blood and give medicines without having to insert new needles into a vein.\n\nLMP744 will be given through the central line for 5 days in a row. Participants will remain in the clinic for this time.\n\nParticipants will then have a second surgery to remove as much of their tumor as possible. They will remain in the clinic until they recover from the surgery. Then they will recover at home after surgery.\n\nParticipants will return to the clinic to receive the study drug for 5 days in a row through the central line, once a month for up to 12 months. Blood tests, heart function tests, and periodic imaging scans will be repeated during these visits.\n\nParticipants will continue to have telehealth visits every 3 months after they stop taking the drug.",[138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],"Recurrent Glioblastoma","Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","Relapsed Cancer","Recurrent Tumor","Glioblastoma Multiforme","Recurring Glioblastoma","Brain and Central Nervous System Tumors","Glioma","Glioblastomas","Grade IV Astrocytoma","GBM","Recurrent Glioma (Glioblastoma Multiforme)","High Grade Glioma","Glioma, Malignant","Brain Cancer",[138,145,154,155,156,157,158,159,152],"Neoplasms","Neoplasms, Nerve Tissue","Neoplasms by Histological Type","Glioblastoma Multiforme (GBM)","Phase I","Phase II",{"date":39,"type":40},{"date":42,"type":22},{"date":163,"type":22},"2032-12-31",{"name":46,"class":47},{"id":166,"slug":4,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":167,"targetDuration":4,"studyType":82,"phases":168,"briefSummary":136,"conditions":169,"keywords":170,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":177,"locationsCount":48},"100624942",{"count":133,"type":22},[84,135],[138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],[138,145,154,155,156,157,158,159,152],"2026-07-01",{"date":173,"type":40},"2026-07-02",{"date":175,"type":22},"2026-07-07",{"date":163,"type":22},{"name":46,"class":47},{"id":179,"slug":4,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":180,"targetDuration":4,"studyType":82,"phases":181,"briefSummary":85,"conditions":182,"keywords":183,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":186,"leadSponsor":187,"locationsCount":48},"100622817",{"count":81,"type":22},[84],[87],[89,90,91,92,93],{"date":173,"type":40},{"date":175,"type":22},{"date":98,"type":22},{"name":46,"class":47},{"id":189,"slug":4,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":58,"conditions":191,"keywords":192,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":195,"leadSponsor":196,"locationsCount":48},"100603509",{"count":57,"type":22},[60,61],[60,63,64,65,66],{"date":173,"type":40},{"date":175,"type":22},{"date":70,"type":22},{"name":46,"class":47},{"id":198,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":200,"keywords":201,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":204,"leadSponsor":205,"locationsCount":48},"100563423",{"count":21,"type":22},[26,27,28,29],[26,31,32,33,34,35],{"date":173,"type":40},{"date":175,"type":22},{"date":44,"type":22},{"name":46,"class":47},{"id":207,"slug":4,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":107,"maxAge":19,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":110,"conditions":209,"keywords":210,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":213,"leadSponsor":214,"locationsCount":48},"100531732",{"count":109,"type":22},[112],[114,115,116,117,118],{"date":173,"type":40},{"date":121,"type":40},{"date":123,"type":22},{"name":46,"class":47},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":82,"phases":223,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":48},"100249911","phase-1-investigation-of-blood-brain-barrier-breakdown-using-manganese-magnetic-resonance-imaging-in-drug-resistant-epilepsy-100249911","NCT02531880","Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy","* INCLUSION CRITERIA:\n* Age 18-60.\n* Able to give written informed consent directly.\n* Drug resistant epilepsy participants will be defined as having clinically documented seizures with consistent EEG evidence as defined by the 1981 International Classification of Epileptic Seizures, refractory to standard anti-seizure treatment for at least one year prior to enrolling in this study and with an average of at least one seizure per month. This criterion will be established by preliminary screening NINDS Epilepsy Service under protocol 18-N-0066. Seizure focus localization will be determined by standard clinical, neurophysiologic, and imaging studies. Prior or concurrent enrollment in 18-N-0066 is required.\n\nEXCLUSION CRITERIA:\n\nGeneral exclusions:\n\n* Patients with epilepsy who are not surgical candidates\n* Significant structural brain abnormality such as a brain tumor, stroke, brain damage from head trauma or blood vessel abnormalities, on the baseline MRI scan.\n* Positive test for HIV\n* Pregnancy or breast-feeding\n* Claustrophobia to a degree that the subject would feel uncomfortable in the MRI machine.\n* Cannot lie on their back for at least two hours.\n* Risk for MRI scan, (e.g., any non-organic implant or other device such as a cardiac pacemaker or infusion pump or other metallic implants, objects or body piercings that cannot be removed, or history of being a welder or metal worker due to small metal fragments in the eye)\n* Unwilling to allow sharing and\u002For use in future studies of coded data that are collected for this study\n\nMEMRI component specific exclusions (applicable only to patients participating in this arm of the study):\n\n* History of post-ictal psychosis or post-ictal aggression\n* Planning to get pregnant in the next 2 months\n* History of clinically significant liver or kidney disease that could potentially increase the risk of CNS damage due to manganese exposure\n* A history of drug or alcohol abuse\u002Fdependence (subjects scoring 8 or higher on the AUDIT scale)\n* Screening lab abnormalities demonstrating values more than 2 times the upper limit of normal for AST, ALT, bilirubin, alkaline phosphatase, BUN, creatinine\n* Previous presumed occupational exposure to manganese (i.e., having worked in a mine, foundry, smelter, dry cell battery manufacturing facility, or agriculture)\n* Allergy to manganese\n* On-going treatment with calcium-channel blocker\n* Iron-deficiency anemia\n* Personal history of Parkinson s Disease or Parkinsonism or presence of this disease in a 1st degree relative\n\nGadolinium enhanced MRI component specific exclusions (applicable only to patients participating in this arm of the study):\n\n* Estimated GFR \\\u003C60, tested within 1 week of scan\n* Allergy to gadolinium\n\nOf note, patients who are ineligible for one arm of the study may still be eligible for and participate in the other arm of the study.","60 Years",{"count":133,"type":22},[84],"Background:\n\n\\- The blood-brain barrier separates the brain from the rest of the body. Epilepsy is a neurological disease that causes seizures. It can affect this barrier. Researchers think a contrast agent called mangafodipir might be better able to show areas of the brain that epilepsy affects.\n\nObjective:\n\n\\- To see if mangafodipir is well tolerated and safe. To see if magnetic resonance imaging (MRI) using either mangafodipir or gadolinium can show areas of blood-brain barrier breakdown in people with epilepsy.\n\nEligibility:\n\n* People ages 18-60 who:\n* Have epilepsy not controlled by drugs\n* Prior or concurrent enrollment in 18-N-0066 is required\n\nDesign:\n\n* Participants will be screened with:\n* Medical history\n* Physical exam\n* Blood and urine tests\n* Participants will have up to 6 visits in 1-3 months. One visit is an inpatient stay lasting 2-10 days. Visits may include:\n* Video-EEG monitoring for participants with epilepsy\n* An IV catheter put in place: a needle guides a thin plastic tube into an arm vein.\n* Getting mangafodipir through the IV.\n* Getting gadolinium through the IV.\n* Up to 6 MRI scans over a 10-day period: a magnetic field and radio waves take pictures of the brain. Participants lie on a table that slides into a metal cylinder. They are in the cylinder for 45-90 minutes, lying still for up to 10 minutes at a time. The scanner makes loud knocking sounds. Participants will get earplugs.\n* A final MRI at least 2 weeks after receiving mangafodipir....",[226],"Epilepsy",[114,228,229,230,231],"Manganese Enhanced MRI","Seizure Disorder","Seizures","Epileptic Focus",{"date":173,"type":40},{"date":234,"type":40},"2024-11-19",{"date":236,"type":22},"2030-07-01",{"name":46,"class":47},{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":244,"sex":17,"minAge":245,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":48},"100468133","nih-investigative-deep-phenotyping-study-of-gulf-war-veteran-health-project-nih-in-depth-100468133","NCT05375812","NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH)","* INCLUSION CRITERIA:\n\nInclusion criteria for all veterans:\n\n* Ability to provide informed consent\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Age 48-70 at time of enrollment into VA IN-DEPTH Study\n* Veterans who were deployed to Gulf Region ODS\u002FS between August 1990 - June 1991.\n* Self-reported completion of at least the seventh grade of school.\n* Fluency in speaking, reading, and understanding English.\n* Underwent screening as part of the VA IN-DEPTH study and were unanimously determined to be eligible by the IN-DEPTH Adjudication Committee.\n* Agree not to smoke in the 4 hours prior to CPET procedure\n\nEXCLUSION CRITERIA:\n\nExclusion criteria for all veterans:\n\n* Current or past psychotic disorder including depression with psychosis, bipolar disorder with psychotic symptoms and schizophrenia\n* Current DSM-5-defined major depression disorder, generalized anxiety disorder, posttraumatic stress disorder, panic disorder, or obsessive-compulsive disorder unless managed for more than six months with a stable treatment regimen\n* Current or past substance use disorder within last five years as diagnosed on the Structured Clinical Interview for DSM-5 (SCID-5). Prior or prescription marijuana use within the past five years will not be an exclusion.\n* Current suicidal ideation\n* History of head injury leading to moderate or severe traumatic brain injury, as detailed by loss of consciousness for greater than 30 minutes, a Glasgow Coma Score of 12 or less at the time of injury, post-traumatic amnesia greater than one day, or brain-scan changes related to a head injury. Persons having a history of mild TBI (mTBI) will not be excluded.\n* Women who are pregnant, breastfeeding, or are within one-year post-partum.\n* Current or previous malignancy. A history of malignancy that has fully resolved with surgical resection only (e.g. no chemotherapy, radiation therapy, or immunotherapy) will be allowed.\n* Current systemic immunologic disorders (e.g. Type 1 diabetes, rheumatoid arthritis). Local immunological disorder (e.g. atopic dermatitis, stable autoimmune thyroid disease) and allergic disorders will be allowed.\n* Current or previous long-term immune suppressive therapy. Systemic steroid use, even short-term, must not have been used within the month prior to enrollment\n* Any medical condition that would make the study procedures risky for the participant (e.g. congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease, severe osteoarthritis, exercise-induced angina and poorly controlled asthma).\n* Active participation in a clinical protocol (e.g. anti-inflammatory drug intervention study) which includes an intervention that may affect the results of the current study.\n* Inability to perform the bicycling exercise task. (e.g. coronary artery disease, not having a lower limb, disabling stroke)\n* Not willing to allow for research data and samples to be shared broadly with other researchers.\n* Symptom severity that makes it impossible for the volunteer to travel to NIH for extended inpatient evaluation\n* Use of medications with a high-risk for withdrawal-related complications (i.e. long-acting opiates or benzodiazepines).\n\nAdditional Exclusion criteria for participants undergoing TMS:\n\n\\- Pacemaker, implanted pump, stimulator, cochlear implant or metal objects inside the eye or skull.\n\nParticipants with unconfirmed metal may have further evaluation to rule out metal in the eye or skull.\n\nParticipants without metal after evaluation may proceed to TMS.\n\n\\- A personal history of seizure disorder\n\nAdditional Exclusion criteria for participants undergoing MRI:\n\n\\- Metal in the body which would make having an MRI scan unsafe, such as pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, artificial heart valves, cochlear implants or shrapnel fragments, or having a history of being a welder or metal worker, since small metal fragments may be in the eye. Participants with unconfirmed metal may have further evaluation to rule out metal in the eye\n\nor skull. Participants without metal after evaluation may proceed to MRI.\n\n* Substantial claustrophobia\n* Inability to lie on back for up to 2 hours\n\nAdditional Exclusion criteria for Healthy Veteran Controls:\n\n\\- Meets modified Kansas criteria for GWI.",true,"48 Years","70 Years",{"count":248,"type":22},85,"Background:\n\nGulf War illness (GWI) affects up to 210,000 U.S. veterans who served in the Middle East during the Gulf War in 1990-1991. Symptoms include fatigue, muscle and joint pain, forgetfulness, headaches, rashes, and sleep disturbances. Routine exams cannot determine the cause of GWI. Researchers need more information to understand this disease.\n\nObjective:\n\nThis natural history study will look for differences in Gulf War veterans who experienced GWI and those who did not.\n\nEligibility:\n\nGulf War veterans with GWI. Healthy Gulf War veterans who do not have GWI are also needed.\n\nDesign:\n\nParticipants will stay in the NIH Clinical Center as an inpatient for 2 weeks. They will undergo many tests.\n\nBlood will be drawn many times throughout the study. Participants will also give urine, saliva, and stool samples.\n\nScans to measure the brain, leg muscles, bone density and body mass will be done.\n\nThey will have an exercise stress test and muscle strength tests.\n\nThey will have a sleep study. They will have tests to look at how well the brain, heart and lungs are working.\n\nParticipants will sleep in a specialized room that measures the amount of oxygen they use and the carbon dioxide they produce on four consecutive nights.\n\nA sample of fluid will be collected from inside the spine.\n\nParticipants will take many surveys. Some will ask about their activities. Some will be about emotional and mental health. Some will be about thinking, memory, and behavior.\n\nOptional tests include other imaging scans and testing the autonomic nervous system. Samples of skin and muscle may be taken.\n\nAfter discharge, participants will wear activity monitors for 14 days. They will keep a diary of their symptoms, including fatigue, pain, and sleep, while wearing the monitors.",[251],"Gulf War Illness",[253,254,255],"Veteran","Gwi (Gulf War Illness)","Natural History","2026-06-27",{"date":258,"type":40},"2026-06-30",{"date":260,"type":40},"2023-04-16",{"date":262,"type":22},"2030-12-31",{"name":46,"class":47},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":272,"conditions":273,"keywords":277,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":48},"100303052","investigating-complex-neurodegenerative-disorders-related-to-amyotrophic-lateral-sclerosis-and-frontotemporal-dementia-100303052","NCT03225144","Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia","* INCLUSION CRITERIA:\n\nPatients will be included if they\n\n* Are age 18 or older\n* Have been given a diagnosis by a neurologist of frontotemporal dementia, primary progressive aphasia, semantic dementia, motor neuron disorder, amyotrophic lateral sclerosis, progressive bulbar palsy, corticobasal syndrome, Huntington disease or other related adult-onset neurodegenerative disorder OR\n* Carry a mutation in a gene that causes familial ALS or FTD\n\nEXCLUSION CRITERIA:\n\nPatients will be excluded if they\n\n* Have other major neurological or medical diseases that may cause progressive weakness or cognitive dysfunction, such as structural brain or spinal cord disease, metabolic diseases, paraneoplastic syndromes, infectious diseases, peripheral neuropathy or radiculopathy or other significant neurological abnormalities.\n* Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe\n* Require daytime ventilator support at the time of study entry\n* Are unable to travel to NIH\n* Patients with pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, or shrapnel fragments, metal fragments in the eye) will not be excluded but will not undergo magnetic resonance imaging.\n* Patients with tattoos above the neck or permanent make up will be excluded from undergoing 7T MRI.",{"count":271,"type":22},360,"Background:\n\nNeurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells. Researchers want to understand whether these diseases have related causes or risk factors.\n\nObjective:\n\nTo test people with movement or thinking and memory problems to see if they are eligible for research studies.\n\nEligibility:\n\nPeople ages 18 and older with a neurodegenerative disorder associated with accumulation of TDP-43 or Tau proteins\n\nDesign:\n\nParticipants will have a screening visit. This may take place over 2-3 days. Tests include:\n\nMedical history\n\nPhysical exam\n\nQuestions about behavior and mood\n\nTests of memory, attention, concentration, and thinking\n\nMovement measurement. The speed at which participants can stand up from a chair, tap their finger and foot, and walk a short distance will be measured. Some movements will be videotaped. They will be videotaped while they speak and read a paragraph.\n\nBlood tests. This might include genetic testing.\n\nLung and breathing tests\n\nMRI. They will lie on a table that slides into a cylinder that takes pictures of the body. Some participants will get a dye through IV.\n\nElectromyography. A thin needle will be inserted into the muscles to measure electrical signals.\n\nNerve tests. Small electrodes on the skin record muscle and nerve activity.\n\nA small piece of skin may be removed.\n\nA skin or blood sample may be taken to create stem cells.\n\nOptional lumbar puncture. A needle will be inserted into the space between the bones of the back to collect fluid.\n\nIf participants are not eligible for current studies, they may be contacted in the future.",[274,275,276],"Frontotemporal Dementia","Amyotrophic Lateral Sclerosis","Progressive Supranuclear Palsy",[278,276,279,274,280,255],"TDP-43","Motor Neuron Disease","Corticobasal Syndrome",{"date":258,"type":40},{"date":283,"type":40},"2017-10-11",{"date":285,"type":22},"2027-10-30",{"name":46,"class":47},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":82,"phases":296,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":48},"100218336","deep-brain-stimulation-therapy-in-movement-disorders-100218336","NCT02119611","Deep Brain Stimulation Therapy in Movement Disorders","* INCLUSION CRITERIA:\n\nTo be eligible for entry into the study, candidates must meet all the following criteria:\n\n* Be 18 years of age or older.\n* Able to comply with study procedures and provide informed consent.\n* Have a clinical diagnosis of idiopathic PD, primary dystonia, or ET:\n\n  1. The diagnosis of idiopathic PD will be based on the UK Brain Bank Criteria, and confirmed by the Movement Disorders Neurologists in the NIH Parkinson Clinic.\n  2. The diagnosis of primary (generalized or segmental), hemidystonia, or cervical dystonia will be confirmed on clinical examination in the NIH Movement Disorders Clinic.\n  3. The diagnosis of ET will be confirmed on clinical examination in the NIH Movement Disorders Clinic (the diagnosis of ET will be based on bilateral, largely symmetric postural or kinetic tremor involving hands and forearms that is visible and persistent. Additional or isolated tremor in head may be present but there should be the absence of abnormal posturing).\n* a. History of appropriate response to dopaminergic medication, with at least a 30% improvement in motor UPDRS with L-DOPA by history or in-clinic testing, for the PD patients. OR\n\n  b.Patients with tremor-dominant PD that do not respond to dopaminergic therapy and that exhibit a tremor score of at least 2 for tremor severity on at least one side of the body on the motor UPDRS examination.\n* Unsatisfactory clinical response to maximal medical management (with trials of both higher and lower doses of drugs), including:\n\nFor PD patients:\n\n1. good benefit from dopaminergic medication but associated with insufficient duration of action or unacceptable side-effects OR\n2. intractable disabling motor fluctuations (severe off periods, dyskinesias, or freezing spells) OR\n\n   For ET and dystonia:\n3. intractable symptoms of ET or dystonia impacting at least 2 activities of daily living.\n\n   * Interested in being evaluated to undergo DBS, if indicated, to treat medically refractory movement disorder or\n   * Patients already implanted with DBS for continued management\n\n(Note: Inclusion criteria 4 and 5 can be met by historical report in patients who had DBS implanted outside the NIH)\n\nEXCLUSION CRITERIA:\n\nFor those who have not had DBS:\n\nCandidates will be excluded if they meet any of the following criteria:\n\n* Clinically significant medical disease that would increase the risk of developing pre- or postoperative complications, including but not limited to uncontrolled systemic hypertension with values above 170\u002F100; unstable heart disease; unstable respiratory disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation which cannot be interrupted;\n* Evidence of secondary or atypical parkinsonism\u002Fdystonia\u002Ftremor as suggested by:\n\n  1. History of stroke, exposure to toxins, neuroleptics, or encephalitis\n  2. Neurologic signs of upper motor neuron or cerebellar involvement, supranuclear gaze palsy, or multiple systems atrophy.\n  3. MR-imaging with evidence indicative of secondary disease such as tumor, or stroke, which could cause the movement disorder.\n* Dementia as evidenced by formal neuropsychological evaluation, Mattis Dementia Rating Scale (DRS-2) score, and clinical evaluations.\n* Unable to complete cognitive assessments and testing necessary to adequately evaluate risks and benefits of surgery.\n* Clinically signficiant or unstable psychiatric disorder such as severe depression or anxiety, which, in the opinion of the investigators would increase the risk of developing postoperative complications.\n* Unable to undergo MR-imaging because of implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have, or if candidates are uncomfortable in small closed spaces (have claustrophobia), or cannot lie comfortably on their back for up to one hour.\n* Pregnant women.\n* Otherwise not eligible for DBS surgery, for example known inability to undergo anesthesia\n\nFor those who have had DBS:\n\n-Contra-indications for ongoing stimulation, such as intractable side effects of DBS despite stimulation parameter adjustment","100 Years",{"count":295,"type":22},300,[297],"NA","Background:\n\n\\- In deep brain stimulation (DBS), a device called a neurostimulator is placed in the chest. It is attached to wires in parts of the brain that affect movement. DBS might help people with movement disorders like Parkinson s disease (PD), dystonia, and essential tremor (ET).\n\nObjective:\n\n\\- To provide DBS treatment to people with some movement disorders.\n\nEligibility:\n\n\\- Adults 18 years and older with PD, ET, or certain forms of dystonia.\n\nDesign:\n\n* Participants will be screened with medical history and physical exam. They will have blood and urine tests and:\n* MRI brain scan. The participant will lie on a table that slides in and out of a metal cylinder with a magnetic field. They will be in the scanner about 60 minutes. They will get earplugs for the loud noises. During part of the MRI, a needle will guide a thin plastic tube into an arm vein and a dye will be injected.\n* Electrocardiogram. Metal disks or sticky pads will be placed on the chest, arms, and legs. They record heart activity.\n* Chest X-ray.\n* Tests of memory, attention, concentration, thinking, and movement.\n* Eligible participants will have DBS surgery. The surgery and hospital care afterward are NOT part of this protocol.\n* Study doctors will see participants 3 4 weeks after surgery to turn on the neurostimulator.\n* Participants will return every month for 3 months, then every 3 months during the first year, and every 6 months during the second year. Each time, participants will be examined and answer questions. DBS placement will be evaluated with MRI. The neurostimulator will be programmed. At two visits, participants will have tests of movements, thinking, and memory....",[300],"Parkinson's Disease",[302,303,300,304,305],"Deep Brain Stimulation","Movement Disorders","Essential Tremor","Tourette Syndrome",{"date":258,"type":40},{"date":308,"type":40},"2014-04-02",{"date":310,"type":22},"2030-12-01",{"name":46,"class":47},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":244,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":4,"leadSponsor":332,"locationsCount":48},"100199675","thinking-and-memory-problems-in-people-with-hiv-100199675","NCT01875588","Thinking and Memory Problems in People With HIV","An Evaluation of HIV-associated Neurocognitive Disorders (HAND) in Virologically Controlled Patients","* INCLUSION CRITERIA:\n\nAll Participants (HIV-infected and HIV-negative Controls):\n\nWhile different individual HIV neurocognitive studies have specific selection criteria, especially related to HIV viral load and antiretroviral therapy, inclusion criteria for this overarching protocol will be flexible in order to identify the broadest base of potential enrollees possible.\n\n1. 18 years of age and older.\n2. Ability to sign informed consent by the participant.\n3. At least seventh grade educational level and ability to speak, read, and understand English. Education level will be assessed by participant self-report. Because many of the neuropsychological subtests were validated using United States norms, participants must be native English speakers or if foreign-born, demonstrate ability to understand the English language at the time of protocol consent and neuropsychological testing.\n4. Consent to store blood and tissue.\n5. Willing to participate in this study for up to 20 years.\n\nHIV-infected Only:\n\n1. HIV-1 infection, as documented by OraQuick rapid test using venipuncture whole blood, or fingerstick whole blood; or with HIV-1\u002FHIV-2 Multispot rapid test and Western Blot as determined by NIH Clinical Pathology Laboratory or Leidos Biomedical Research. Monitoring Laboratory.\n2. Outside primary medical doctor who provides care.\n3. Plasma HIV-RNA \\\u003C50 copies\u002Fmm3 or BLD for greater than one year. Participants who experience transitory episodes of an HIV viral load \\> 50 copies\u002Fmm3 preceded and followed by plasma viremia \\\u003C 50 copies\u002Fmm3 may be included.\n4. At least one year of continuous ART.\n\nHIV-negative Controls Only:\n\n1.HIV-antibody negative but can be taking pre-exposure prophylaxis (PrEP).\n\nEXCLUSION CRITERIA:\n\n1. Illness or other condition that, in the opinion of the PI, may interfere with study participation at the time of enrollment, including, but not limited to those listed below:\n\n   1. CNS infections: this includes but is not limited to Varicella zoster virus (VZV) encephalitis, CNS lymphoma and toxoplasmosis. Participants who have recovered from effectively treated CNS infections may be considered once they resume baseline daily activities.\n   2. Non-CNS opportunistic infections: Participants who recovered from or are completing treatment for non-CNS opportunistic infections (Ois) (e.g., Pneumocystis pneumonia, Candida esophagitis, or pulmonary TB) can be enrolled if they have returned to self-reported baseline activity and functional level.\n2. Conditions other than HAND associated with cognitive impairment or dementia such as Alzheimer's, Parkinson's disease, head injury with loss of consciousness \\>30 minutes, untreated sleep apnea with day-time sleepiness, or seizure disorders. Participants with a history of seizure disorder with no seizure activity that are on a stable, non-sedating anti-seizure regimen for \\>6 months may be enrolled.\n3. Concurrent severe, unstable psychiatric illness that, in the opinion of the investigators, may interfere with study participation and\u002For data interpretation. Participants on psychotropic anxiolytic, attention deficit-hyperactivity disorder (ADHD), and other psychiatric medications may be included if clinically stable for 6 months.\n4. Concurrent substance abuse that, in the opinion of the investigators may interfere with study participation and\u002For data interpretation. Active substance abuse includes illegal drug use and\u002For excessive narcotic or alcohol use as determined by the investigator. Urine drug screen will be performed on all participants. Use of nicotine containing products will not be an exclusion criterion.\n5. Contraindication to MRI scanning, including pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), implanted delivery pump, or shrapnel fragments. Participants requiring a low dose oral benzodiazepine for mild to moderate claustrophobia will be allowed to participate. Pregnancy testing will be performed in enrolled participants of childbearing potential 48 hours prior to any MRI.\n6. Medications: narcotics, psychiatric, and anti-seizure medications will not be allowed except under certain conditions as noted above. Corticosteroids may be permitted for participants on stable short-term therapy without CNS disease (i.e. resolving Pneumocystis pneumonia). Participants must be willing not to take the following medications within 48 hours of neuropsychological testing: sedating antihistamines such as diphenhydramine, zolpidem and other drugs identified by the study team that are associated with altered alertness or impaired memory.\n7. Prior or planned\u002Fanticipated exposure to radiation due to clinical care or participation in other research protocols, which would exceed the recommended acceptable annual limit of radiation exposure once accounting for the requirements of the current study.\n8. Pregnant persons are excluded due to exposure to high magnetic fields There is also exposure to radiation from the lumbar puncture if done under fluoroscopy. Participants of childbearing potental must have a negative serum or urine pregnancy 48 hours prior to any radiation exposure.",{"count":320,"type":22},1150,"Background:\n\n\\- People with human immunodeficiency virus (HIV) can sometimes develop thinking and memory problems. These problems can vary widely, from few symptoms to severe problems with memory and concentration. It initially was thought that good HIV treatment could prevent almost all HIV-related memory problems. However, even people with low HIV viral loads can have these problems. It may be caused by HIV affecting the brain and spinal fluid. It is not yet clear why HIV causes these problems and why they may be worse in some people than others. Researchers want to study people with HIV and healthy volunteers to see how HIV may affect people with only small amounts of the virus in their blood.\n\nObjectives:\n\n\\- To study thinking and memory problems in individuals with HIV that is otherwise controlled with medications.\n\nEligibility:\n\n* Individuals between 18 of age or older whose HIV has been controlled with medications for at least 1 year.\n* Healthy volunteers between 18 of age or older.\n\nDesign:\n\n* Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. A neurological test will also be given. Participants will have a baseline imaging study of the brain.\n* Within 12 weeks of the first visit, participants will have a second visit. Additional blood samples will be drawn. Another brain imaging study will be performed.\n* Within 8 weeks of the second visit, participants will have a third visit to collect more blood samples. They will also provide spinal fluid samples, either as a single visit or a longer procedure.\n* After this visit, participants will return every 12 months for up to 10 years. Blood samples will be collected as needed at these visits. Thinking and memory tests and imaging studies may also be given as needed. Spinal fluid may be collected at one visit a year.",[323],"HIV Positive",[325,323,326,327,328,255],"Healthy Controls","Neuropyschological Testing","Thinking and Memory","Lumbar Drain\u002FPuncture",{"date":258,"type":40},{"date":331,"type":40},"2013-07-08",{"name":46,"class":47},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":244,"sex":17,"minAge":18,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":4,"leadSponsor":358,"locationsCount":48},"100054743","evaluation-of-patients-with-hamtsp-100054743","NCT00001778","Evaluation of Patients With HAM\u002FTSP","Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM\u002FTSP)","* INCLUSION CRITERIA:\n\nParticipants that meet one of the following criteria:\n\n* Test positive for HTLV infection (positive HTLV-1 ELISA followed by a positive Western blot)\n* Positive HTLV ELISA but a Western Blot that only partially fulfills the above criteria (seroindeterminate)\n* Have a family member\u002Fsignificant other who is HTLV positive, and may have been exposed to the virus\n* Healthy volunteer AND\n* Willingness to participate in the protocol evaluations and procedures.\n\nEXCLUSION CRITERIA:\n\n* Unwillingness or inability to participate in the protocol evaluations and procedures.\n* The presence of any medical, social, or psychiatric conditions that in the opinion of the investigator may affect the safety of the patients or compliance with the protocol.\n* Patients\u002Fhealthy volunteers under the age of 18 are excluded.","120 Years",{"count":342,"type":22},750,"Objective:\n\nHuman T-lymphotropic virus type-I-associated myelopathy \u002F tropical spastic paraparesis (HAM\u002FTSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus. The purpose of this protocol is to study the natural history of HAM\u002FTSP by monitoring clinical progression of patients longitudinally. Additionally, we will attempt to define the virological and immunological changes of HAM\u002FTSP.\n\nStudy Population:\n\nPatients with HAM\u002FTSP who fulfill World Health Organization diagnostic criteria are eligible to participate in this protocol. Asymptomatic seropositive individuals and individuals with indeterminate HTLV-1 serology are also eligible to participate.\n\nDesign and Outcome Measures:\n\nA longitudinal assessment of clinical, virological and immunological progression in HAM\u002FTSP will be accomplished through periodic testing and evaluation. Asymptomatic seropositive individuals, those with seroindeterminate HTLV-I serology and normal volunteers may serve as controls. Longitudinal standardized neurological examinations will be performed. Longitudinal samples of serum, plasma, and lymphocytes may be obtained from participants. Lumbar punctures may be performed on all participants. These samples will be used virological and immunological assays. A focus is on the relationships between the characteristics of viral infection, the immune response, and the genetic makeup.\n\n...",[345,346],"HTLV-I Infection","Tropical Spastic Paraparesis",[348,349,350,351,352,255,353,354],"Immune Response","Sero-Indeterminant","Transmission","HTLV-1","HTLV-1 Associated Myelopathy","HTLV-I","HAM\u002FTSP",{"date":258,"type":40},{"date":357,"type":40},"1998-04-06",{"name":46,"class":47},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":366,"targetDuration":4,"studyType":82,"phases":368,"briefSummary":369,"conditions":370,"keywords":372,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":48},"100632235","phase-2-intravenous-brincidofovir-as-an-antiviral-for-treatment-of-progressive-multifocal-leukoencephalopathy-a-pilot-study-100632235","NCT07511049","Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study","Safety and Tolerability of Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study","* INCLUSION CRITERIA:\n* Able to provide informed consent\n* Stated willingness to comply with study procedures and to participate for the duration of the study including follow-up\n* Actively progressing, clinically definite or probable PML (2013 AAN Consensus Diagnostic Criteria)\n* Positive PCR for JCPyV in CSF\n* Age 18 or older\n* Medically stable and able to tolerate travel to NIH\n* Participants of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study\n\nEXCLUSION CRITERIA:\n\n* ALT or AST \\> 5 x the ULN, total bilirubin \\> 3 mg\u002FdL (SI: \\>51 micromol\u002FL), or spontaneous prothrombin time-international normalized ratio (PT-INR) \\> 2 x ULN within 7 days prior to Day 1\n* An estimated glomerular filtration rate of \\\u003C 30 mL\u002Fmin within 7 days prior to Day 1\n* Hypersensitivity to CDV or to BCV or its formulation excipients, or prior intolerance to these agents that, in the opinion of the investigator, would pose an unacceptable safety risk.\n* Active CNS disease other than PML that, in the opinion of the investigator, would confound study assessments or pose an unacceptable safety risk.\n* Contraindication to MRI (including cardiac pacemakers and some infusion pumps, other metallic implants, metallic foreign objects)\n* Medical contraindication to LP\n* Positive pregnancy test or nursing",{"count":367,"type":22},24,[135],"Background:\n\nProgressive multifocal leukoencephalopathy (PML) is a rare and often fatal brain infection caused by the JC virus. The JC virus is common. More than half of adults have been exposed to it. Most people do not get sick from the JC virus, but in people with weakened immune systems, it can cause PML. Brincidofovir (BCV) is an antiviral drug approved to treat smallpox. Researchers want to know if it can help people with PML.\n\nObjective:\n\nTo test BCV in people with PML.\n\nEligibility:\n\nPeople aged 18 years or older with PML.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood tests. They will have an imaging scan of the brain with contrast dye. They will have a lumbar puncture (spinal tap): A thin needle will be inserted into their lower back to draw out a sample of the fluid around their spinal cord.\n\nBCV will be given through a tube attached to a needle inserted into a vein. Participants will receive the drug 2 times a week for 4 weeks (this is 1 cycle). If the drug is helping them, they may have up to 3 drug cycles (12 weeks).\n\nImaging scans, spinal taps, and other tests will be repeated after every 4 weeks of treatment. Participants will have 6 follow-up visits in 1 year after treatment ends. The imaging scan, spinal tap, and other tests will be repeated at each visit.",[371],"Progressive Multifocal Leukoencephalopathy",[373,374],"Safety and Tolerability of Intravenous Brincidofovir","safety, tolerability, brincidofovir, PML, JCV","2026-06-25",{"date":377,"type":40},"2026-06-26",{"date":379,"type":40},"2026-06-05",{"date":381,"type":22},"2029-12-31",{"name":46,"class":47},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":17,"minAge":390,"maxAge":19,"enrollmentInfo":391,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":48},"100564551","a-prospective-natural-history-and-outcome-measure-validation-study-of-congenital-myasthenic-syndromes-100564551","NCT06630650","A Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic Syndromes","A Single Center Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic Syndromes","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged \\>= 6 months of age\n* Clinically stable as evidenced by medical record review and remote screening questionnaire\n* Genetically confirmed congenital myasthenic syndrome (pathogenic or likely pathogenic variants identified by CLIA testing in an established CMS-related gene including but not limited to DOK7, COLQ, CHRNE, RAPSN, CHAT, GFPT1, DPAGT1 OR pathogenic\u002Flikely pathogenic variant in combination with a variant of uncertain significance (VUS) AND additional clinical supporting evidence of CMS).\n* Agreement to adhere to Lifestyle Considerations throughout study duration\n* Ability of subject to understand and the willingness to provide informed consent (\\>=18 years of age) and assent (\\>=7 years of age).\n\nEXCLUSION CRITERIA:\n\n* Received gene transfer therapy\n* Pregnant women (prior to enrollment)\n* Ongoing medical condition or medication use that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study or safety of the subject.","6 Months",{"count":57,"type":22},"Background:\n\nCongenital myasthenic syndromes (CMSs) are a group of inherited disorders that affect how the nerves communicate with muscles. These can cause many problems that affect how people can move and use their bodies.\n\nObjective:\n\nThis is a natural history study to learn more about how CMSs affect the body and cause changes over time.\n\nEligibility:\n\nPeople aged 6 months or older with a CMS. The study will focus on DOK7- and COLQ-related CMSs, as well as other forms.\n\nDesign:\n\nParticipants will have up to 7 visits in 5 years. At each visit, participants will undergo many tests, including:\n\nPhysical exam with blood and urine tests.\n\nTests of their heart and lung function.\n\nExams of the eyes, lungs, muscles, and nerves. These will be done with different specialists.\n\nExams of the arms and hands and of body use and movements. These will also be done with specialists.\n\nPhotos and videos may be taken.\n\nMuscle ultrasound. Participants will lie still as a wand is rubbed over their skin.\n\nMagnetic resonance imaging (MRI) scans. Participants will lie still on a bed that slides partway into a large tube. A parent or other person may remain in the room, too. The scan will take 60 minutes.\n\nElectromyography (EMG). Participants will lie still or may be asked to move around. A machine will measure the electrical activity in their muscles.\n\nAn activity monitor may be placed on the participant s wrist, ankle, or hip for up to 2 weeks. The monitor is about the size of a wristwatch.\n\nA sample of skin may be removed....",[394],"Myasthenic Syndromes, Congenital",[396,397,398,399,400],"Congenital Myasthenic Syndrome","Collagen Q","Downstream of tyrosine kinase 7","DOK7","COLQ",{"date":377,"type":40},{"date":403,"type":40},"2025-05-12",{"date":405,"type":22},"2044-12-02",{"name":46,"class":47},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":244,"sex":17,"minAge":413,"maxAge":293,"enrollmentInfo":414,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":416,"conditions":417,"keywords":420,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":426,"locationsCount":48},"100471009","natural-history-protocol-for-movement-disorders-100471009","NCT05413291","Natural History Protocol for Movement Disorders","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 2 and above\n* Either one of these:\n\n  * Have or suspected to have a diagnosis of a movement disorder.\n  * Family member of someone who has or is suspected of having a diagnosis of a movement disorder.\n* Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets the following criteria will be excluded from participation in this study:\n\n-Being \\\u003C 2 years old.","2 Years",{"count":415,"type":22},4000,"Background:\n\nA movement disorder is a condition that causes a person s body to move in ways that are not normal. There are different types. Some disorders cause movements people can t control, such as tics or shaking. Some cause reduced or slow movements. Movement disorders can cause disability in people. Sometimes members of the same family will have the same disorder. Researchers want to learn more about how people develop these disorders. This research could lead to better treatments.\n\nObjective:\n\nThis natural history study will collect data on people with different types of movement disorders. It will also collect data on their family members. The data will support further research.\n\nEligibility:\n\nChildren and adults aged 2 years and older who have a movement disorder. Family members of people with movement disorders are also needed.\n\nDesign:\n\nParticipants will undergo screening. They will have a physical exam. Researchers will look at their existing medical images. Any photographs or videos of their movements will also be reviewed.\n\nMost participants will come to the NIH clinic for only 1 visit. They will answer questions about their condition. They will have normal tests used to diagnose their condition. They may have blood tests and different types of imaging scans. They may have tests to see how well their nerves function. The tests used will depend on the type of disorder they have.\n\nFamily members will have some of the same tests as people with disorders.\n\nParticipants will not receive any new treatments.\n\nSome participants may be asked to return for a follow-up visit.\n\nUp to 4000 people may participate.",[418,419,300],"Movement Disorder","Tremor",[418,419,300,255],"2026-06-24",{"date":375,"type":40},{"date":424,"type":40},"2022-10-17",{"date":262,"type":22},{"name":46,"class":47},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":17,"minAge":413,"maxAge":293,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":435,"conditions":436,"keywords":437,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":4,"leadSponsor":446,"locationsCount":48},"100059578","phenotypegenotype-correlations-in-movement-disorders-100059578","NCT00018889","Phenotype\u002FGenotype Correlations in Movement Disorders","* INCLUSION CRITERIA:\n* Individuals with suspected movement disorders\n* Family members of movement disorders patients\n* Ability to give informed consent or have a legally authorized representative able to give consent (for adults without consent capacity) or parent\u002Fguardian able to provide informed consent (for a child)\n* If unable to give informed consent, ability to give assent (for children or adults without consent capacity)\n* NIH Employees can participate in this study if they meet eligibility.\n\nEXCLUSION CRITERIA:\n\n* Pregnant women\n* Children less than 2 years of age\n* Employees of the Parkinson's Disease Clinic, NINDS\n\nExclusion criteria for MRI\n\n* Presence of metal in subject s body which would make having an MRI scan unsafe, such as pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, artificial heart valves, cochlear implants or shrapnel fragments, or if subject was a welder or metal worker, since small metal fragments in the eye may be present.\n* Subject is uncomfortable in small closed spaces (have claustrophobia) so that they would feel uncomfortable in the MRI machine.\n* Unable to lie comfortably on back for up to 1 hour\n* Under 12 years of age\n\nThere is no general exclusion for NIH employees.",{"count":434,"type":22},2500,"The goal of this protocol is to identify families with inherited movement disorders and evaluate disease manifestations to establish an accurate clinical diagnosis by using newest technological advances and investigate the underlying molecular mechanisms. Studies of inherited movement disorders in large families with good genealogical records are especially valuable. Patients with diseases of known molecular basis will be genotyped in order to investigate phenotype\u002Fgenotype correlation. Patients with disease of unknown or incomplete genetic characterization will be studied with a hope of contributing to the identification of specific disease-causing genes and genetic mechanisms responsible for a specific disorder.",[418],[438,439,304,440,441,255,418,442],"Clinical Evaluation","Genetic Study","Familial Myoclonus","Hereditary Ataxia","Inherited Movement Disorder",{"date":375,"type":40},{"date":445,"type":40},"2001-10-22",{"name":46,"class":47},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":340,"enrollmentInfo":454,"targetDuration":4,"studyType":82,"phases":456,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":48},"100269228","phase-2-effect-of-corticosteroids-on-inflammation-at-the-edge-of-acute-multiple-sclerosis-plaques-100269228","NCT02784210","Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques","The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study","* INCLUSION CRITERIA:\n* Multiple sclerosis, as defined by the 2017 Revised McDonald Criteria;\n* Age 18 or older;\n* Ability to provide informed consent;\n* Able to participate in study procedures and provide high-quality clinical research and imaging data, based on limited artifacts on prior MRI scans and, when possible to determine;\n* Presence of a gadolinium enhancing lesion on the screening (3T or 7T) brain MRI that demonstrates either centripetal\u002Frim enhancement or a phase rim, or both;\n* Simultaneously participates in another screening or natural history protocol within the NINDS Neuroimmunology Clinic at the time of study entry.\n* Willing to use birth control if able to conceive a child\n\nEXCLUSION CRITERIA:\n\n* Medical contraindications for MRI (e.g., any non-organic implant or other device such as a cardiac pacemaker or infusion pump or other metallic implants, objects, or body piercings that are not MRI-compatible or cannot be removed);\n* Psychological contraindications for MRI (e.g., claustrophobia), to be assessed at the time the medical history is collected;\n* Treatment with systemic steroids in previous 30 days (non-systemic administration of steroids, such as topical or local injection, is acceptable);\n* Experiencing new neurological symptoms, with onset in previous 2 weeks, attributable to MS relapse;\n* Pregnancy or current breastfeeding;\n* Screening labs, only if required per current NIH Clinical Center guidelines for kidney-function screening before gadolinium-based MRI contrast, demonstrating estimated glomerular filtration rate \\\u003C60 mL\u002Fmin;\n* Known hypersensitivity to gadolinium-based contrast agents;\n* Medical contraindications to corticosteroid administration (e.g., diabetes, gastric ulcer)",{"count":455,"type":22},30,[135],"Background:\n\nMultiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many ways. Sometimes they light up from the outer edge and fill inward. This is called ring enhancement. Researchers think this type of lesion may not heal as well as others. Corticosteroids are the standard treatment to reduce symptoms of MS relapse. But there is no standard treatment for people with enhancing MS lesions without signs of MS relapse. Researchers want to see if a short-term high-dose course of corticosteroids helps heal those lesions.\n\nObjective:\n\nTo study the effects of short-term high-dose corticosteroids on ring-enhancing MS.\n\nEligibility:\n\nAdults ages 18 and older who:\n\n* Have MS and a rim-enhancing lesion on a prior brain MRI\n* Are enrolled in another NINDS protocol\n\nDesign:\n\nParticipants will be screened under another protocol\n\nParticipants will be randomly assigned to get either no treatment or 3 days of treatment with a corticosteroid.\n\nParticipants will have:\n\n* 1 baseline visit\n* 3 days of high-dose steroids, intravenous or oral. If IV, participants will receive methylprednisolone by IV each day. Participants will also be prescribed medicine to protect their stomach.\n* Follow-up visits will be at week 13 and week 25 after randomization to treatment or no treatment.\n\nVisits include medical history and physical exam. Participants will have blood and urine tests. Participants will also have neurological exams and MRIs. Participants lie on a table that slides into a cylinder. They are in the scanner 1.5-2 hours. They get a dye through a catheter: A needle guides a thin plastic tube into an arm vein.",[459],"Multiple Sclerosis",[461,114,462,463,464],"Centripetal Enhancement","7 Tesla","Gadolinium","MS","2026-06-23",{"date":421,"type":40},{"date":468,"type":40},"2016-10-05",{"date":470,"type":22},"2028-12-31",{"name":46,"class":47},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":244,"sex":17,"minAge":478,"maxAge":340,"enrollmentInfo":479,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":486,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":48},"100217448","noninvasive-pre-surgical-evaluation-of-patients-with-focal-epilepsy-and-establishment-of-a-normative-imaging-database-100217448","NCT02107989","Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database","* INCLUSION CRITERIA FOR PATIENTS:\n* Age 8 and older\n* Evaluated or under evaluation for epilepsy surgery under protocol 18-N-0066,11-N-0051 or 16-N-0041\n* Documentation of focal epilepsy based on MRI, EEG and\u002For ictal semiology\n* Ability to give informed consent, have or be able to assign a legally authorized representative able to give consent (for adults without consent capacity), or parent\u002Fguardian able to provide informed consent (for a child).\n\nINCLUSION CRITERIA FOR PATIENTS SOLELY CONTRIBUTING DATA:\n\n* Had epilepsy surgery with presurgical evaluation under 18-N-0066\n* Age 8 and up at the time of epilepsy surgery evaluation\n* Had a preoperative structural brain MRI of the type used in this protocol\n\nINCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:\n\n* Age 8 and older\n* Ability to give informed consent or have a parent\u002Fguardian able to provide informed consent if a child.\n* Ability to cooperate with MRI scanning without anesthesia\n\nEXCLUSION CRITERIA FOR PATIENTS:\n\n* Contraindications to MRI or MEG studies (such as pacemakers, cochlear implants, shrapnel, permanent eyeliner)\n* Claustrophobia or anxiety disorders exacerbated by the MRI scanner\n* Pregnancy. All females of childbearing potential must have a negative pregnancy test prior to MRI scanning\n\nEXCLUSION CRITERIA FOR PATIENTS SOLELY CONTRIBUTING DATA:\n\n-Not able or willing to give consent or do not have an appropriate surrogate who can provide consent\n\nEXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:\n\n* Contraindications to MRI or MEG studies (such as pacemakers, cochlear implants, shrapnel, permanent eyeliner)\n* Claustrophobia or anxiety disorders exacerbated by the MRI scanner\n* Significant medical conditions that may affect the central nervous system, such as psychiatric disorders (such as mood disorders, psychotic disorders, substance abuse or dependence), significant neurologic disorders (such as brain injury, neurodegenerative disorders, multiple sclerosis, stroke, movement disorders, epilepsy), or active systemic disease that may affect the central nervous system (such as uncontrolled hypertension, autoimmune disorders or other inflammatory disorders, neoplastic disease)\n* Use of centrally acting medications in the past 6 weeks, such as benzodiazepines, barbiturates, antidepressants, beta-blockers, and drugs for treating epilepsy or migraine\n* Pregnancy. All females of childbearing potential must have a negative pregnancy test prior to MRI scanning","8 Years",{"count":480,"type":22},700,"Objectives:\n\nThe overall study objective is to compare the sensitivities and specificities of morphometric analysis techniques using structural MRI images based on pre- and postsurgical localization of epileptic foci in patients undergoing presurgical evaluation for medically refractory epilepsy. To carry out these analyses, we aim to establish an age-stratified normative imaging database using healthy volunteers. Additional objectives are to identify abnormal networks in these patients using resting state fMRI\u002FEEG and MEG\u002FEEG, and to use language and memory fMRI tasks to examine the effects of epileptogenic zones and surgery on cognitive function and the networks associated with these functions.\n\nStudy population:\n\n300 adults and children (age 8 and older) with uncontrolled focal epilepsy, and 200 age-stratified healthy volunteers.\n\nDesign: A retrospective and prospective natural history study. Research procedures for patients in this study include neuropsychological testing and 1-4 MRI sessions during presurgical evaluation and an additional 1-3 MRI sessions and neuropsychological testing approximately 12 months post-operatively. Research testing (such as research neuropsychological tests or MRI scanning sequences) will be done during a visit for clinical testing whenever possible, likely reducing the number of required visits. Patients will also have optional MEG and 7T structural imaging. Data will also be obtained from patients who have already undergone epilepsy surgery if they had procedures as outlined in the protocol and are willing to share the data. Healthy volunteers will receive a subset of the pre-operative procedures for patients, requiring at least 3 visits. In order to ensure adequate data acquisition, subjects may be re-scanned up to three times for the portions of the study in which they participated, possibly requiring additional visits.\n\nOutcome measures:\n\nThe main outcomes will be establishment of normative values for morphometric analysis methods in age-stratified normal controls, and comparison of the sensitivity and specificity of these measures to pre- and postsurgical localization of the epileptogenic zone. Secondary outcome measures will include determination of the sensitivity and specificity of source localization using MEG\u002FEEG and resting state fMRI\u002FEEG, and to evaluate changes in activation during rest, as well as language and memory fMRI tasks in patients pre- and postsurgically, to examine the effects of epileptogenic zones and surgery on cognitive function and the networks underlying these functions.",[226],[226,114,484,485,255],"fMRI","MEG",{"date":421,"type":40},{"date":488,"type":40},"2014-03-11",{"date":490,"type":22},"2028-03-30",{"name":46,"class":47},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":244,"sex":17,"minAge":413,"maxAge":79,"enrollmentInfo":499,"targetDuration":4,"studyType":82,"phases":501,"briefSummary":502,"conditions":503,"keywords":507,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":48},"100201553","electrical-impedance-myography-natural-history-studies-inneuromuscular-disorders-and-healthy-volunteers-100201553","NCT01900132","Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers","Electrical Impedance Myography: Natural History Studies in Neuromuscular Disorders and Healthy Volunteers","* INCLUSION CRITERIA:\n\nHEALTHY VOLUNTEERS-ADULTS\n\n1. Healthy adults, male or female, aged 18 years old or older,\n2. In good general health as evidenced by medical history\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nHEALTHY VOLUNTEERS-PEDIATRIC\n\n1. Healthy children, male or female, age 7-18,\n2. In good general health as evidenced by medical history\n3. Stated willingness to comply with all study procedures and availability for the duration of the study\n4. Ability of subject or Legally Authorized Representative (LAR)) to understand and the willingness to sign a written informed consent document.\n\nSUBJECTS WITH NEUROMUSCULAR DISEASE\n\nAdult and pediatric, male or female, patients with a neuromuscular disorder are eligible even if the exact etiology of the disorder is unknown at the time of enrollment into this study. This will include neuropathy, myopathy and motor neuron disorders. It is expected that the subjects are undergoing appropriate standard diagnostic and genetic work-up outside of this protocol that will later clarify the specific etiology of the disorder. Movement disorder will also be included because of the prior research done on dystonia and EIM.\n\nInclusion criteria\n\n1. Suspected motor neuron disease or\n2. Suspected myopathy or\n3. Suspected neuropathy or\n4. Suspected movement disorders that impair intracortical processes\n5. Age of 2 years or older\n6. Ability of subject to sign a written informed consent document.\n\nNIH EMPLOYEES:\n\nNIH employees and staff may participate, however EMG Section, OCD, NINDS, employees may not participate.\n\nEXCLUSION CRITERIA:\n\nHEALTHY VOLUNTEERS-ADULTS\n\n1. Medical conditions that require medications that affects the physiological measures being tested. Some conditions that may be excluded are diabetes, kidney and liver disease.\n2. History of stroke, muscle disorders, peripheral neuropathy or spine surgery\n\nHEALTHY VOLUNTEERS-PEDIATRIC\n\n1. Medical conditions that require medications that affects the physiological measures being tested. Some conditions that may be excluded are diabetes, kidney and liver disease.\n2. History of stroke, muscle disorders, peripheral neuropathy or spine surgery\n\nSUBJECTS WITH NEUROMUSCULAR DISEASE:\n\nNo clinical evidence of a neuromuscular disorder on clinical evaluation.",{"count":500,"type":22},275,[297],"Background:\n\n\\- Electrical impedance myography (EIM) is a new technique being studied to see if it is helpful in evaluating muscle disorders and nerve disorders. EIM looks at how a mild, painless electrical current travels through muscles. Researchers want to gain experience in using the EIM device. They will collect information on the results of using it on people with and without nerve and muscle diseases, and compare that with information from other standard tests. First, they will test the device on healthy people. Then they will test people with a variety of neuromuscular diseases. Because the test is noninvasive and not painful, researchers will test both children and adults.\n\nObjectives:\n\n\\- To gain experience using the EIM muscle testing device.\n\nEligibility:\n\n* Healthy volunteers at least 2 years old.\n* Individuals at least 2 years old who have neuromuscular disease.\n\nDesign:\n\n* Participants will be screened with a medical history and physical exam.\n* Participants will have one 2-3 hour clinic visit. Researchers may request follow-up visits.\n* Participants will be tested with the EIM device. The device and small electrodes will be placed on their skin. An electric current will pass through the device, but the participants will not feel this.\n* Participants may have an ultrasound test. A gel will be put on their skin, and a device will be moved over the skin.\n* Participants may have a nerve test. Electrodes will be placed on their skin, and they will feel a small shock.\n* Participants may have a test where a thin needle is inserted in their muscle.",[504,279,505,506],"Neuromuscular Disease","Inherited Neuromuscular Conditions","Inherited Neuropathies",[508,504],"Electrophysiology",{"date":421,"type":40},{"date":511,"type":40},"2013-06-20",{"date":513,"type":22},"2027-06-01",{"name":46,"class":47},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":244,"sex":17,"minAge":413,"maxAge":340,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":522,"conditions":523,"keywords":524,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":4,"leadSponsor":531,"locationsCount":48},"100188552","natural-history-study-of-progressive-multifocal-leukoencephalopathy-pml-100188552","NCT01730131","Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)","* PML Patients\n\nINCLUSION CRITERIA:\n\n1. Suspected or confirmed PML\n2. MRI compatible with PML\n3. Able to participate in the studies and follow-up required by the protocol\n4. At least 2 years old\n\nEXCLUSION CRITERIA:\n\n1. Significant condition, which in the judgment of the principal investigator, would make participation in the diagnostic and research parts of evaluation impossible or risky\n2. Medical contraindication to MRI (i.e., devices such as a cardiac pacemaker or infusion pump, other metallic implants, metallic foreign objects, body piercings that cannot be removed)\n3. Pregnancy\n4. Inability to provide informed consent, either directly or via legally authorized representative (LAR)\n5. Unwillingness to consent for collection of biological samples or their cryopreservation\n\nControl Patients at Risk for PML\n\nINCLUSION CRITERIA:\n\n1. Able to participate in the studies and follow-up required by the protocol\n2. At least 2 years old\n3. Impaired immune function from any cause and considered at risk for PML (i.e.-history of hematological malignancy, chronic inflammatory disease, history of treatment with immune suppressive or immunomodulatory therapies, primary or acquired immunodeficiency syndromes)\n\nEXCLUSION CRITERIA:\n\n1. Significant condition, which in the judgment of the principal investigator, would make participation in the diagnostic and research parts of evaluation impossible or risky\n2. Medical contraindication to MRI (i.e., devices such as a cardiac pacemaker or infusion pump, other metallic implants, metallic foreign objects, body piercings that cannot be removed)\n3. Pregnancy\n4. Inability to provide informed consent, either directly or via legally authorized representative (LAR)\n5. Unwillingness to consent for collection of biological samples or their cryopreservation\n\nHealthy Volunteers\n\nINCLUSION CRITERIA:\n\n1. Able to participate in the studies and follow-up required by the protocol\n2. At least 18 years old\n\nEXCLUSION CRITERIA:\n\n1. Impaired immune function (i.e.-history of hematological malignancy, chronic inflammatory disease, history of treatment with immune suppressive or immunomodulatory therapies, primary or acquired immunodeficiency syndromes)\n2. Significant condition, which in the judgment of the principal investigator, would make participation in the diagnostic and research parts of evaluation impossible or risky\n3. Medical contraindication to MRI (i.e., devices such as a cardiac pacemaker or infusion pump, other metallic implants, metallic foreign objects, body piercings that cannot be removed)\n4. Pregnancy\n5. Inability to provide informed consent, either directly or via legally authorized representative (LAR)\n6. Unwillingness to consent for collection of biological samples or their cryopreservation",{"count":480,"type":22},"Background:\n\n\\- Progressive multifocal leukoencephalopathy (PML) is a severe viral infection of the brain. It is caused by JC virus. Many people have this virus in their bodies all their life, but it is usually kept in check by their immune system. If the immune system does not work right because of a disease or medication, the virus becomes active and can damage cells in the brain. Not much is known about PML or how it affects the immune system. Researchers want to study people with PML to better understand the natural history of the disease.\n\nObjectives:\n\n\\- To study the natural history of PML.\n\nEligibility:\n\n\\- Individuals at least 2 years of age who have PML.\n\nDesign:\n\n* Participants will be screened with a physical exam, medical history, and imaging studies.\n* Participants will have several visits to the National Institutes of Health Clinical Center. There will be an initial visit, monthly visits for the next 6 months, a 12-month visit, and possible visits afterward.\n* At the initial visit, participants will give blood, urine, and spinal fluid samples. They will also have neurological tests and imaging studies of the brain.\n* For the next five visits, participants will give blood and urine samples. They will also have neurological tests and imaging studies of the brain.\n* The 6-month and 12-month visits will repeat the tests from the initial visit.\n* Other optional procedures include bone marrow samples and skin biopsies. Additional blood tests and imaging studies may be performed.\n* Treatment will not be provided as part of this study.",[371],[525,526,527,459,255],"Encephalitis","Immune Reconstitution Syndrome","Human Immunodeficiency Virus",{"date":421,"type":40},{"date":530,"type":40},"2012-11-08",{"name":46,"class":47},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":478,"maxAge":539,"enrollmentInfo":540,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":542,"conditions":543,"keywords":545,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":4,"leadSponsor":554,"locationsCount":48},"100102587","natural-history-study-of-patients-with-neurofibromatosis-type-2-100102587","NCT00598351","Natural History Study of Patients With Neurofibromatosis Type 2","A Prospective Natural History Study of Patients With Neurofibromatosis Type 2 (NF2).","* INCLUSION CRITERIA:\n\nTo be eligible for entry into the study, candidates must meet all the following criteria:\n\n* Have the diagnosis of NF2 by established clinical criteria or genetic testing.\n* Be between the age of 8 and 75.\n* Have the capacity to undergo serial MRI scanning of the CNS without IV sedation.\n* Able to give informed consent, or have a parent able to provide informed consent if a child.\n\nEXCLUSION CRITERIA:\n\nCandidates will be excluded if they:\n\n* Have a clinically unstable condition that precludes serial clinical and imaging evaluation (i.e. Class 3 congestive heart failure, severe chronic renal insufficiency, severe chronic obstructive pulmonary disease).\n* Cannot have an MRI scan due to an allergy or relative contraindication to MRI contrast agents, prior surgery or implant that involves metal clips or wires, which might be expected to cause tissue damage or produce image artifacts such as pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, and artificial heart valves.\n* ABIs or cochlear implants are not approved by the NIH Radiology department for safe use on NIH scanners..\n* Have severe chronic renal insufficiency (glomerular filtration rate less than 30 mL\u002Fmin\u002F1.73 m2), hepatorenal syndrome or post-liver transplantation.\n* Are pregnant at time of intake visit (women of childbearing age will be tested with a urine pregnancy test).","75 Years",{"count":541,"type":22},269,"Objective\n\nWith this prospective natural experiment trial on neurofibromatosis type 2 (NF2) study, we hope to understand the factors leading to tumor progression and neurological disease burden in NF2.\n\nStudy Population\n\nA total of 269 participants, ages 8-75, with a clinical or genetic diagnosis of NF2 will participate in this study.\n\nDesign\n\nStudy participants will be evaluated with a thorough physical and neurologic examination upon enrollment. This initial outpatient evaluation will include magnetic resonance imaging with contrast of brain and spine and blood collection for research use. Participants with measurable hearing will have audiology assessment performed. Participants with untreated vestibular schwannomas will have vestibular assessment performed during the initial visit. Genetic studies performed outside will be acceptable as confirmation of NF2 in enrolled patients. If needed to confirm NF2 with genetic studies, or for research purpose, whole genome\u002Fwhole exome sequencing may be performed on blood obtained from subjects enrolled in this study. All participants will be evaluated by a speech language pathologist.\n\nSubjects will be followed as outpatients for up to ten years, during which clinical, and radiologic evaluation will be performed annually. Auditory testing will be performed annually for participants with measurable hearing. Participants with initially untreated vestibular schwannomas will be followed annually with vestibular testing. Speech and swallowing reassessments will be repeated if worsening of speech or swallowing is reported. Blood will be collected at each visit for blood biomarker testing\n\nOutcome measures\n\nWe hope to understand the biologic basis for speech and swallowing dysfunction in patients with NF2. We will study and report the strength of association of MRI findings, clinical assessments cranial nerve deficits and speech\u002Fswallowing dysfunction. We hope to\n\nidentify imaging biomarkers of hearing loss in NF2. We will attempt to discover the mode of peripheral neuropathy in patients with NF2. Lastly, we will attempt to discover previously unknown serum biomarkers associated with high tumor burden in NF2.\n\n...",[544],"Neurofibromatosis",[546,547,548,549,550,255],"Meningioma","Ependymoma","Schwannoma","Spinal Cord Tumor","Vestibular Schwannoma",{"date":421,"type":40},{"date":553,"type":40},"2008-03-21",{"name":46,"class":47},""]